Other News To Note
Tuesday, June 18, 2013
• Transition Therapeutics Inc., of Toronto, said Eli Lilly and Co., of Indianapolis, exercised its option to assume all development and commercialization rights to Type II diabetes drug candidate TT-401.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.